A new data portal called Cancer-Immu established by a team of biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. With data from 3,652 samples for 16 cancer types, Cancer-Immu is the largest immune checkpoint blockade-related data portal for exploring immunogenomic connections.